Top UK Facility Achieves Funding Success
Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
Clinical researchers at St George’s, University of London, U.K. have used crowd-funding methods based on donations and rewards to raise cash for a Phase II trial in 140 bowel cancer patients on the FutSci platform.
The campaign has reached its target of £50,000 (approximately $75K) in the first 45 days, according to Dr Deepika Kassen, PhD, Director of FutSci. To date it has been backed by 320 people from 16 countries and has raised £53,088.88 ($80564.76). There are still 10 days left of the campaign.
Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) Tu Youyou, in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
The campaign is a collaboration between the researchers, FutSci, Bowel Disease UK and the Anticancer Fund. The researchers are using the money to top-up funds they already have from charity. Budget cuts mean the research is not funded by government/institutional bodies, and the pharmaceutical industry is not interested because it is a relatively cheap drug, noted Kassen.
More information is available at www.futsci.com/project/antimalarial-cancer.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
